Abata Therapeutics Reports the US FDA’s IND Clearance for P-I Trial of ABA-101 for Progressive Multiple Sclerosis
Shots:
- The US FDA has cleared the IND application to commence FIH P-I trial of ABA-101 for treating progressive multiple sclerosis (MS), anticipated by the YE'24
- The in vivo non-clinical study depicted ABA-101’s tolerability and its ability of producing anti-inflammatory cytokines & suppressing inflammatory cytokines with antigen-dependent Treg functionality
- ABA-101 is an autologous Treg therapy developed by utilizing patient’s Tregs for expressing TCR to target immunogenic myelin fragments in the CNS, inducing localized anti-inflammatory effect at the disease site
Ref: Abata Therapeutics | Image: Abata Therapeutics
Related Posts:- Atara Biotherapeutics Reports Results for ATA188 in P-II Trial for the Treatment of Non-Active Progressive Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
